Peter J Sciavolino, PhD


Distinct Genomic Differences Evident in Younger Patients With Lung Cancer

February 5th 2016

Clinical trial findings have implications for expanding the use of genomic testing—and thereby potentially increasing treatment options—for the younger lung cancer population.

Importance of BRAF Testing Grows as Options Expand in Melanoma

December 28th 2015

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

Debating the Merits of New Therapeutic Stars in NSCLC

October 29th 2015

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

More Aggressive Therapy Options Are on the Table for Elderly Patients With HCC

August 4th 2015

Pierre M. Gholam, MD, discusses managing elderly patients with advanced HCC, including current practices and emerging strategies.

FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma

February 23rd 2015

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Molecular Markers Emerge in the Diagnosis of Thyroid Cancer

December 9th 2014

Although prognostic biomarkers have become increasingly important in the treatment of many types of cancer, no such markers have yet been identified and validated for thyroid cancer.

Aprepitant Yields Significant Benefits for the Prevention of CINV in Children

June 28th 2014

Aprepitant is significantly more effective than a comparator placebo-added regimen in preventing CINV in children, with benefits seen across all phases of treatment.

Enobosarm May Prevent Cancer-Induced Muscle Wasting in NSCLC

June 28th 2014

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

Two Phase III Trials Find Rolapitant Effective, Well-Tolerated for Preventing CINV

June 28th 2014

A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.

Single-Dose of Dexamethasone Adequate With Palonosetron for Controlling CINV

June 28th 2014

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.

Aprepitant- and Metoclopramide-Based Regimens Demonstrate Similar Efficacy in Preventing Delayed Cisplatin-Induced Emesis

June 27th 2014

For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.